Table 1.
Patients' characteristics.
| nRCTx (n = 130) |
control group (n = 30) |
||||
|---|---|---|---|---|---|
| n/median (range) | % | n/median (range) | % | p | |
| Sex | |||||
| male | 96 | 73.8 | 20 | 66.7 | n.s. |
| female | 34 | 26.2 | 10 | 33.3 | |
| Age (y) | 61.0 (36–82) | 67.6 (22–76) | |||
| ≤ 65 | 88 | 67.7 | 12 | 40.0 | 0.005 |
| > 65 | 42 | 32.3 | 18 | 60.0 | |
| NCTx | |||||
| 5-FU | 117 | 90.0 | — | — | — |
| others | 13 | 10.0 | — | — | — |
| Accumulated radiation dose [in Gy] | |||||
| 46.8 | 1 | 0.8 | — | — | — |
| 50.4 | 125 | 96.2 | — | — | — |
| 55.8 | 4 | 3 | — | — | — |
| Death | |||||
| Yes | 45 | 34.6 | 13 | 43.3 | n.s. |
| No | 85 | 65.4 | 17 | 56.7 | |
| Metastases in follow up | |||||
| Yes | 39 | 30.0 | 7 | 23.3 | n.s. |
| liver | 5 | 12.8 | 1 | 14.3 | |
| lung | 7 | 17.9 | 0 | 0.0 | |
| others | 6 | 15.4 | 0 | 0.0 | |
| No | 91 | 70.0 | 23 | 76.7 | |
| Local recurrence | |||||
| Yes | 10 | 7.7 | 2 | 6.7 | n.s. |
| No | 120 | 92.3 | 28 | 93.3 | |
| Follow up [months] | 59.8 (0.3–155.5) | 106.9 (12.9–163.4) | |||
Abbreviations: n.s.: not significant (P>0.05); 5-FU: 5-fluorouracil; nCTx: neoadjuvant chemotherapy; Gy: Gray.